Jefferies LLC is a U.S.-based broker-dealer and investment banking firm and the primary operating subsidiary of Jefferies Group LLC, part of Jefferies Financial Group. The firm provides mergers and acquisitions advisory, equity and debt underwriting, restructuring, and capital markets services, alongside equity and fixed income research, sales, and trading for corporate, financial sponsor, and institutional clients globally.
For the chemical industry, Jefferies maintains dedicated sector coverage spanning petrochemicals, specialty chemicals, industrial gases, and materials. Its teams advise on corporate transactions (including acquisitions, divestitures, carve-outs, and joint ventures), support equity and debt financings, and publish sector research that informs investors and industry participants. Jefferies operates across the Americas, EMEA, and Asia-Pacific, facilitating public and private market execution for companies throughout the chemicals value chain.
Q2 net loss $6M, adjusted EBITDA $120M; free cash flow used $90M; signed all‑stock merger with Olin; stockholder vote Aug 25, 2026.
Includes two late-stage ROS1 and ALK NSCLC inhibitors under FDA review for 2026 decisions, plus a HER2 candidate; expected to be accretive to profit from 2027 and funded by debt and cash.
Buyer will acquire a clinical-stage in vivo CAR-T developer for up to $7B (incl. $3.25B upfront). Lead KLN-1010 (lentiviral anti-BCMA) showed promising Phase 1 ASH data; close expected H2 2026.
$38/ADS cash + up to $9 CVR (max $47/sh); upfront equity ~$6.3B (CVR ~$1.5B). Lead OX2R agonist cleminorexton showed positive Phase 2a for narcolepsy and idiopathic hypersomnia. Close expected Q3
Acquirer to buy target biotech at $53/share (~$6.7B equity, ~$5.7B net). Lead oral allosteric BCR::ABL1 TKI showed week‑24 molecular responses in Phase1/2; expected Q2 2026.
Ventyx's small molecule pipeline targets chronic inflammation in cardiometabolic, neurodegenerative, and inflammatory diseases, aiming for improved efficacy and safety.
